Luye Pharma Group Ltd.
LYPHFOTCHealthcare● Active
$0.40
+$0.07(+20.50%)
Market Cap$1.6B
P/E Ratio—
52W High$0.395
52W Low$0.268
Luye Pharma Group Ltd. (LYPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LYPHF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.15B | $6.06B | $6.14B | $5.98B | $5.20B |
| Cost of Revenue | $2.09B | $2.02B | $1.94B | $1.84B | $1.80B |
| Gross Profit | $4.06B | $4.04B | $4.20B | $4.14B | $3.40B |
| Gross Margin %(computed) | 65.99% | 66.72% | 68.44% | 69.22% | 65.32% |
| Operating Expenses | |||||
| R&D Expenses | $0.40B | $0.50B | $0.59B | $0.86B | $0.68B |
| G&A Expenses | $0.00B | $0.58B | $0.64B | $0.58B | $0.57B |
| Total Operating Expenses | $2.84B | $2.75B | $3.18B | $3.19B | $3.11B |
| Operating Income | $1.21B | $1.29B | $1.03B | $1.21B | $0.39B |
| Operating Margin %(computed) | 19.70% | 21.30% | 16.75% | 20.31% | 7.44% |
| Interest Income | $0.09B | $0.08B | $0.12B | $0.09B | $0.10B |
| Interest Expense | $0.67B | $0.56B | $0.68B | $0.47B | $0.40B |
| Income Before Tax | $0.92B | $0.84B | $0.70B | $0.67B | ($0.07B) |
| Income Tax Expense | $0.23B | $0.19B | $0.16B | $0.09B | $0.07B |
| Net Income | $0.60B | $0.47B | $0.53B | $0.60B | ($0.14B) |
| Net Margin %(computed) | 9.81% | 7.79% | 8.67% | 10.11% | -2.78% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.15 | $0.02 | $0.14 | $0.17 | $-0.04 |
| Wtd Avg Shares | 3.90B | 3.76B | 3.73B | 3.48B | 3.45B |
| EBITDA | $2.03B | $2.19B | $2.08B | $1.81B | $0.91B |
| EBITDA Margin %(computed) | 33.01% | 36.16% | 33.82% | 30.31% | 17.44% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more Luye Pharma Group Ltd. data
About Luye Pharma Group Ltd. (LYPHF) Income Statement
Luye Pharma Group Ltd. (LYPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LYPHF reported revenue of $6.15B, gross profit of $4.06B (gross margin 65.99%), and net income of $0.60B — a net profit margin of 9.81%.
Frequently asked questions
LYPHF · 4 questionsLuye Pharma Group Ltd. (LYPHF) reported revenue of $6.15B for 2025, up 1.4% year-over-year.
LYPHF revenueLYPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09